Message-ID: <22588041.1075840993716.JavaMail.evans@thyme> Date: Tue, 8 Jan 2002 14:56:41 -0800 (PST) From: isnoffers@123jump.com To: alewis@enron.com Subject: Profiting from the 2002 biotech boom. Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-From: "ISN Member Offers" @ENRON X-To: alewis@enron.com X-cc: X-bcc: X-Folder: \ExMerge - Lewis, Andrew H.\Deleted Items X-Origin: LEWIS-A X-FileName: andy lewis 6-25-02.PST ChangeWave: Biotech Boom

The drug industry’s deadly little secret
that almost nobody knows!

Today’s $48-billion drug industry is hiding a deadly little secret: 106,000 deaths and 2.2 million injuries a year from drug side effects.

That makes prescription drugs—even when taken exactly as prescribed—the fourth leading cause of death in this country. Not much of a cure.

But what if you discovered five companies that use the newly mapped human genome sequence to predict how you individually will respond to drugs?

Their patented “bioinformatics” technologies could save hundreds of thousands of lives a year. Imagine: Drugs with a market of one. One person, for whom the drug will be designed to be nearly 100% effective.

This reality is closer than you think.

The great thing for investors is, virtually no one knows anything about it.

Yet.

I’m Tobin Smith, founder of ChangeWave Investment Research and author of the New York Times best seller ChangeWave Investing: Picking the Next Monster Stocks of the New Economy.

If you think infotech was big, wait until you really learn about biotech. Because when the scribes write the history of our time, the bursting of the tech-bubble won’t be the lead story. The lead story will be biotech—specifically, the genomics revolution.

Biotech Sector Gives Investors Great Opportunity—Despite Recent Setbacks

You might not understand the science behind genomics. That’s ok. Because what you really need to understand is that the bioeconomy means one thing for savvy investors: Huge profits... IF you own the right stocks. IF you really find out where the winners are, and why they’ll win.

The five companies profiled in Biotech Boom!—ChangeWave’s FREE special report—are the real deal. They already have a lot of these ‘miracle’ drugs progressing through their respective “pipelines.” They are the up-and-coming leaders of the biotech story—the elite group of forward-thinking, profit-generating companies whose products give investors a once-in-a-lifetime shot (literally!) at capitalizing on the profits locked in the human gene sequence.

Companies like:

  • Biotech Boom Stock #1: A deal maker with nearly $2 billion in cash in its coffers. Currently engaged in the development of breakthrough drugs and predictive medicine called “gene to patient.” Its anticancer drug was brought to market in an incredible 18 months! The royalties from this breakthrough might be in the billions! Companies currently funding its growth include Eli Lilly and Bristol Myers Squibb.

  • Biotech Boom Stock #2: The leader in capturing the most sought after intellectual property in the proteomics sector. This future Game Over Dominator just entered the drug development with plans to license the targets it develops to the monsters of Big Drug Inc. This company is the leading candidate to dominate this potential multi-billion dollar industry.

  • Biotech Boom Stock # 3: This leading genomics-based drug company and development company is revolutionizing the industry by merging biology with information technology. There’s no aspect of a person’s life that will not be affected by this company’s work. Recently announced a huge landmark biotechnology agreement with Bayer. Keep an eye on this one!

  • Biotech Boom Stock # 4: You might call this company the “Intel of Biotech.” Its intellectual property consists of the microchip arrays that are used for DNA testing. If personalized, genomics-based drugs take off, this chip is the proprietary technology that will be widely used in testing. A huge opportunity for big profits.

  • Biotech Boom Stock #5: A development-stage company that is the potential grand slam in the post-genomics sector. Its partner list reads like a Who’s Who of the drug world including GlaxoSmithKline, Bayer, Johnson & Johnson, and Pharmacia. .

When it comes to biotech, the five stocks profiled in Biotech Boom! are the pick of the litter. But you’ll have to get them before they grow up. There’s simply no time to waste. Although I can’t give you all the details here, I reveal them in your FREE special report, Biotech Boom! To get your FREE COPY, just click here.

Sincerely,


Tobin Smith
Founder, ChangeWave

ChangeWave
Copyright © 2002 ChangeWave Investment Research, LLC. All rights reserved.
Questions? Contact us so we can help.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
This message was not sent to you unsolicited. You are
currently subscribed to this mailing list.To change or
cancel your subscription please click here:
http://123jump.com/letters.htm?S=L&email=alewis@enron.com
Thank you.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~